John Libbey Eurotext

The association between CCL2 polymorphisms and drug-resistant epilepsy in Chinese children Volume 15, issue 3, September 2013


See all figures

Department of Neurology, Clinical Research Center, Department of Pharmacology, Wuhan Children's Hospital, Wuhan, China, Authors contributed equally

The treatment of drug-resistant epilepsy remains a major challenge, affecting approximately 30% of epilepsy patients. More recently, immunity and inflammation are considered to be key elements of epilepsy. Targeting brain inflammation may represent a novel therapeutic strategy for epilepsy and refractory epilepsy. In this study, we investigated the association of a tag SNP of the CCL2 gene, rs1024611 (originally designated as -2578G>A or -2518G>A) with drug-resistant epilepsy in Chinese children with epilepsy. We enrolled 484 epilepsy patients, including 98 drug-resistant patients and 386 drug-responsive patients. The rs1024611 was genotyped by PCR-RPLP. The rs1024611 AA genotype was associated with a greater susceptibility to drug-resistant epilepsy ( p=0.008; OR=2.51, 95% CI: 1.33-4.72), adjusted for age, sex, and seizure type, and the association remained significant after Bonferroni correction for multiple testing ( p<0.05). Our results demonstrate that the CCL2 genetic polymorphism is associated with drug-resistant epilepsy in Chinese paediatric patients.